Drugs / BI 1820237
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06352424 | Apr 2024 → Feb 2025 | obesity disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05751226 | Apr 2023 → Aug 2024 | obesity disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04903509 | Jun 2021 → Aug 2022 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 1820237 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05751226 ↗ |
| Route | Subcutaneous | “Single Rising Subcutaneous Doses of BI 1820237 Alone” NCT04903509 ↗ |